Zobrazeno 1 - 6
of 6
pro vyhledávání: '"R G, Amado"'
Publikováno v:
Annals of Oncology. 13:582-588
Background: 5-Fluorouracil (5-FU)-based regimens have not been shown to prolong survival or provide clinical benefit in patients with advanced pancreatic cancer. The purpose of this study was to determine the tolerability of protracted venous infusio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e4a052f256f501bc47a0218bfaed901
https://doi.org/10.1093/annonc/mdf090
https://doi.org/10.1093/annonc/mdf090
Autor:
R G, Amado, I S Y, Chen
Publikováno v:
Current topics in microbiology and immunology. 261
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1add2a0162e6d3036d2240d4851c15de
https://pubmed.ncbi.nlm.nih.gov/11892250
https://pubmed.ncbi.nlm.nih.gov/11892250
Autor:
I. S. Y. Chen, R. G. Amado
Publikováno v:
Current Topics in Microbiology and Immunology ISBN: 9783642626678
In recent years, enormous advances have been made in our understanding of HIV pathogenesis and in the development of effective therapeutic strategies to combat HIV infection. Combination antiretroviral drugs can effectively reduce HIV RNA in peripher
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba4e8e92b19190ae7b566ddae15c058f
https://doi.org/10.1007/978-3-642-56114-6_12
https://doi.org/10.1007/978-3-642-56114-6_12
Autor:
R G, Amado, G J, Schiller
Publikováno v:
Seminars in oncology. 27(2 Suppl 5)
Significant advances in the field of sickle cell disease (SCD) in recent years have contributed to improving the life expectancy and symptoms of patients with this disease. These health care improvements include the implementation of infectious proph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::63e4a826671f7ef3dfa3276043d23751
https://pubmed.ncbi.nlm.nih.gov/10877059
https://pubmed.ncbi.nlm.nih.gov/10877059
Publikováno v:
Journal of Clinical Oncology. 28:e15128-e15128
e15128 Background: Treatment for mRCC has changed dramatically since 2005. The phase III trials of sorafenib, sunitinib, pazopanib, and bevacizumab + interferon (IFN) were all best supportive care ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e6d343298d46ec186b905830f966dbad
https://doi.org/10.1200/jco.2010.28.15_suppl.e15128
https://doi.org/10.1200/jco.2010.28.15_suppl.e15128
Autor:
E. Van Cutsem, S. Siena, Y. Humblet, J.-L. Canon, J. Maurel, E. Bajetta, B. Neyns, D. Kotasek, A. Santoro, W. Scheithauer, S. Spadafora, R. G. Amado, N. Hogan, M. Peeters
Publikováno v:
Annals of Oncology. Jan2008, Vol. 19 Issue 1, p92-92. 1p.